MindImmune Therapeutics agrees to acquire two programs from H. Lundbeck

MINDIMMUNE THERAPEUTICS has entered into an agreement with Lundbeck tow acquire two programs related to neuropathic pain and Huntington's disease. / COURTESY MINDIMMUNE THERAPEUTICS
MINDIMMUNE THERAPEUTICS has entered into an agreement with Lundbeck tow acquire two programs related to neuropathic pain and Huntington's disease. / COURTESY MINDIMMUNE THERAPEUTICS
SOUTH KINGSTOWN –MindImmune Therapeutics Inc. has entered into agreements with H. Lundbeck A/S to acquire programs and will develop candidates from these programs as novel therapeutics to treat neuropathic pain and Huntington’s disease, the company announced Wednesday. The programs target two neuroinflammation targets: P2X7 receptors and KMO, an enzyme in the neuroimmune kynurenine-signaling pathway, according…

Want More Free?

To access 2 more articles, please log in or register for free.

Registered users get access to a limited number of free articles every month.

Register Now

Already registered? Login to access more free articles.

Purchase NowWant to share this story? Click Here to purchase a link that allows anyone to read it on any device whether or not they are a subscriber.

- Advertisement -